



Interactive Effects of μ -Opioid and Adrenergic- α_2 Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine[§]

Samuel Obeng,  Francisco Leon, Avi Patel, Julio D. Zuarth Gonzalez, Lucas Chaves Da Silva, Luis F. Restrepo, Lea R. Gamez-Jimenez, Nicholas P. Ho, Maria P. Guerrero Calvache, Victoria L.C. Pallares, Justin A. Helmes, Sakura K. Shiomitsu, Paul L. Soto, Aidan J. Hampson, Christopher R. McCurdy, Lance R. McMahon,  Jenny L. Wilkerson, and Takato Hiranita¹

Departments of Pharmacodynamics (S.O., A.P., J.D.Z.G., L.C.D.S., L.F.R., L.R.G.-J., N.P.H., M.P.G.C., V.L.C.P., J.A.H., S.K.S., L.R.M., J.L.W., T.H.), Medicinal Chemistry (S.O., F.L., C.R.M.), and Pharmaceutics (C.R.M.), and Translational Drug Development Core (C.R.M.), Clinical and Translational Sciences Institute, College of Pharmacy, University of Florida, Gainesville, Florida; Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina (F.L.); Department of Psychology, Louisiana State University, Baton Rouge, Louisiana (P.L.S.), Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, Amarillo, Texas (L.R.M., J.L.W., T.H.); Department of Pharmaceutical, Social and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, Alabama (S.O.); Department of Pharmacology, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas (T.H.); and Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland (A.J.H.)

Received March 7, 2022; accepted September 9, 2022

ABSTRACT

The primary kratom alkaloid mitragynine is proposed to act through multiple mechanisms, including actions at μ -opioid receptors (MORs) and adrenergic- α_2 receptors ($A\alpha_2$ Rs), as well as conversion in vivo to a MOR agonist metabolite (i.e., 7-hydroxymitragynine). $A\alpha_2$ R and MOR agonists can produce antinociceptive synergism. Here, contributions of both receptors to produce mitragynine-related effects were assessed by measuring receptor binding in cell membranes and, in rats, pharmacological behavioral effect antagonism studies. Mitragynine displayed binding affinity at both receptors, whereas 7-hydroxymitragynine only displayed MOR binding affinity. Compounds were tested for their capacity to decrease food-maintained responding and rectal temperature and to produce antinociception in a hotplate test. Prototypical MOR agonists and 7-hydroxymitragynine, but not mitragynine, produced antinociception. MOR agonist and 7-hydroxymitragynine rate-decreasing and antinociceptive effects were antagonized by the opioid antagonist naltrexone but not by the $A\alpha_2$ R antagonist yohimbine. Hypothermia only resulted from reference $A\alpha_2$ R agonists. The rate-decreasing and hypothermic effects of reference $A\alpha_2$ R agonists were antagonized by yohimbine but not naltrexone.

Neither naltrexone nor yohimbine antagonized the rate-decreasing effects of mitragynine. Mitragynine and 7-hydroxymitragynine increased the potency of the antinociceptive effects of $A\alpha_2$ R but not MOR reference agonists. Only mitragynine produced hypothermic effects. Isobolographic analyses for the rate-decreasing effects of the reference $A\alpha_2$ R and MOR agonists were also conducted. These results suggest mitragynine and 7-hydroxymitragynine may produce antinociceptive synergism with $A\alpha_2$ R and MOR agonists. When combined with $A\alpha_2$ R agonists, mitragynine could also produce hypothermic synergism.

SIGNIFICANCE STATEMENT

Mitragynine is proposed to target the μ -opioid receptor (MOR) and adrenergic- α_2 receptor ($A\alpha_2$ R) and to produce behavioral effects through conversion to its MOR agonist metabolite 7-hydroxymitragynine. Isobolographic analyses indicated supra-additivity in some dose ratio combinations. This study suggests mitragynine and 7-hydroxymitragynine may produce antinociceptive synergism with $A\alpha_2$ R and MOR agonists. When combined with $A\alpha_2$ R agonists, mitragynine could also produce hypothermic synergism.

The present study was supported by National Institutes of Health National Institute on Drug Abuse [Grants R01-DA025267 and UG3-DA048353-01] (to C.R.M. and L.R.M.), University of Florida Foundation and University of Florida Department of Pharmacodynamics Funding.

No author has an actual or perceived conflict of interest with the contents of this article.

¹Current affiliation: Department of Pharmacology, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas.
dx.doi.org/10.1124/jpet.122.001192.

[§] This article has supplemental material available at jpet.aspetjournals.org.

Introduction

Prescription μ -opioid receptor (MOR) agonists are a primary medication class to treat severe pain (Haq et al., 2021; Montgomery, 2022). However, due to the current high incidents of opioid overdose in the United States (Mattson et al., 2021),

ABBREVIATIONS: $A\alpha_2$ R, adrenergic- α_2 receptor; $A\alpha_{2C}$ R, adrenergic- α_{2C} receptor; CI, confidence interval; DOR, δ -opioid receptor; FR, fixed ratio; i.p., intraperitoneally; Ki, inhibition constant; KOR, κ -opioid receptor; LED, light-emitting diode; MG, mitragynine; MOR, μ -opioid receptor; %MPE, percent maximum possible antinociceptive effect; 7-OH-MG, 7-hydroxymitragynine; p.o., orally by gavage; U69, 593, (+)-(5 α , 7 α , 8 β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide.

there is the need for novel analgesics that are equally effective as MOR agonists but are safer. One of the adverse effects of MOR agonists is the development of dependence and withdrawal. The current medications to treat opioid dependence and withdrawal are either MOR or adrenergic- α_2 receptor ($A\alpha_2$ R) agonists.

Mitragyna speciosa (kratom), a plant native to Southeast Asia, is used as a self-remedy to alleviate opioid withdrawal symptoms in countries such as Malaysia and Thailand (Singh et al., 2014). The use of kratom has increased significantly in the West where kratom products are used for pain reduction and opioid dependence, as well as recreationally (Lydecker et al., 2016; Sharma et al., 2019). Mitragynine (MG), the primary alkaloid in kratom, has received much attention due to its MOR activity (Matsumoto et al., 1996; Shamima et al., 2012; Harun et al., 2015; Varadi et al., 2016; Kruegel et al., 2019; Obeng et al., 2020; Chakraborty et al., 2021; Obeng, Wilkerson et al., 2021). However, MG appears to have a complex pharmacology that may include $A\alpha_2$ R activity. For example, the antinociceptive effects of MG were reversed by both opioid (naltrexone) and $A\alpha_2$ R (yohimbine and idazoxan) antagonists (Matsumoto et al., 1996; Kruegel et al., 2019; Foss et al., 2020).

Decreased overreliance on prescription MOR agonists for pain management could be achieved by combining MOR agonists with nonopioid analgesics, thereby reducing the analgesic dose of the prescribed MOR agonist (i.e., opioid-sparing effect) (Wilkerson et al., 2016; Wilkerson et al., 2017; Wilkerson et al., 2019; Obeng, Hiranita et al., 2021). Although the antinociceptive effectiveness of $A\alpha_2$ R agonists is generally lower than that of MOR agonists, $A\alpha_2$ R agonists have well-established opioid-sparing effects and have been safely used (Crassous et al., 2007; Giovannoni et al., 2009; Tonner, 2017; Valverde and Skelding, 2019). It has been hypothesized that the basis of $A\alpha_2$ R agonist opioid-sparing effects is due to antinociceptive synergism (supra-additivity) between agonists at these receptors. For example, an inactive dose of the $A\alpha_2$ R agonist clonidine (0.016 mg/kg) increased the antinociceptive potency of morphine four- to fivefold without producing tolerance in the mouse tail flick assay (Spaulding et al., 1979). The opioid-sparing effects of $A\alpha_2$ R agonists have been demonstrated regardless of rodent species (i.e., mouse and rat), antinociceptive assays (e.g., hotplate, tail pressure, formalin), and combinations of agonists at these receptors (Drasner and Fields, 1988; Ossipov, Lozito et al., 1990; Plummer et al., 1992; Meert and de Kock, 1994; Stone et al., 1997; Hao et al., 2000; Tajerian et al., 2012; Stone et al., 2014). Importantly, antinociceptive synergism was not accompanied with nonspecific motor (rotarod and open field tests) or cardiovascular (pulse oximetry) disruptions (Tajerian et al., 2012; Stone et al., 2014). Additionally, the adverse effects of the $A\alpha_2$ R agonists are far less severe than those of the MOR agonists (Walker et al., 2002). In marked contrast to the MOR agonists, $A\alpha_2$ R agonists have low, if any, potential for development of abuse and dependence (Arnsten and Li, 2005; Clemow and Walker, 2014; Gowing et al., 2016) which suggests that $A\alpha_2$ R agonists may be ideal for reducing opioid use and overdose. Given the capacity of the $A\alpha_2$ R agonists to reduce opioid use as well as the agonistic activity of MG at MOR and $A\alpha_2$ R as previously mentioned (Matsumoto et al., 1996; Kruegel et al., 2019; Foss et al., 2020; Chakraborty et al., 2021), we hypothesized that MG mitigates opioid withdrawal through dual agonism at these receptors.

Herein, we first assessed preclinical interaction profiles of reference agonists at MOR (methadone and morphine) and $A\alpha_2$ R (lofexidine and clonidine) in rats by measuring effects of drugs on schedule-controlled responding for food, response latency in the hotplate test, and rectal temperature (Boxwalla et al., 2010). Interactions between agonists at the κ -opioid receptor [KOR, (+)-(5 α ,7 α ,8 β)-*N*-methyl-*N*-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide (U69,593)] and $A\alpha_2$ R were also investigated. The mechanism underlying the activity of these compounds was further investigated using antagonists at the MOR (naltrexone) and $A\alpha_2$ R (yohimbine). Isobolographic analyses were conducted to investigate synergism between MOR and $A\alpha_2$ R agonists. In addition, we compared the contribution of MOR and $A\alpha_2$ R to the activity of MG and 7-hydroxymitragynine (7-OH-MG), a MOR active metabolite of MG (Kruegel et al., 2019). A receptor binding assay was employed to assess affinity of test compounds at these receptors.

Methods and Materials

Compounds

The following are sources of compounds: [3 H][D-Ala², D-Leu⁵]-enkephalin ([3 H][D-Ala², D-Leu⁵]-enkephalin) (PerkinElmer, Boston, MA), [3 H][D-Ala², *N*-MePhe⁴, Gly-ol]-enkephalin ([3 H][D-Ala², *N*-MePhe⁴, Gly-ol]-enkephalin) (PerkinElmer), [3 H]2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1*H*-imidazole (PerkinElmer), [3 H]U69,593 (PerkinElmer), clonidine hydrochloride (XGen Pharmaceuticals DJB, Inc., Horseheads, NY), lofexidine hydrochloride (Sigma-Aldrich Co., St. Louis, MO), (-)-methadone hydrochloride (National Institute on Drug Abuse, Drug Supply Program, Rockville, MD), (-)-MG hydrochloride [extracted as described in Hiranita et al. (2019)], (-)-7-OH-MG [semisynthesized from MG as in Obeng, Wilkerson et al. (2021)], (-)-morphine sulfate pentahydrate (National Institute on Drug Abuse), (-)-naltrexone hydrochloride (Sigma-Aldrich), U69,593 (Sigma-Aldrich), and yohimbine hydrochloride (Sigma-Aldrich). Dose/concentration is expressed as the weight of the previously listed salt form or as a base if no salt form is noted. For in vitro studies, compounds were dissolved in dimethyl sulfoxide (Sigma-Aldrich) to form stock concentrations of 10 mM. For behavioral studies, a vehicle consisting of sterile water containing 5% Tween 80 (polyoxyethylenesorbitanmonooleate; Sigma-Aldrich) and 5% propylene glycol (Sigma-Aldrich) was used. Compounds and vehicle were administered intraperitoneally in a volume of 1.0 to 10 mL/kg per body weight. MG and vehicle were also administered subcutaneously and orally via gavage in volumes of 1.0 to 10 mL/kg.

In Vitro Receptor Binding Assay

[3 H]2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1*H*-imidazole (PerkinElmer) was used to label both the human $A\alpha_{2A}$ R and adrenergic- α_{2C} receptor ($A\alpha_{2C}$ R) (O'Rourke et al., 1994). These two $A\alpha_2$ R subtypes were chosen because they are involved in antinociception (Brede et al., 2004). L- α -2A (ATCC CRL11180) and L- α -2C (ATCC CRL-11181) L-cells (American Type Culture Collection, Manassas, VA) were used for the $A\alpha_{2A}$ R and $A\alpha_{2C}$ R, respectively. [3 H][D-Ala², D-Leu⁵]-enkephalin, [3 H]U69,593, and [3 H][D-Ala², *N*-MePhe⁴, Gly-ol]-enkephalin were used to label the human δ -opioid receptor

(DOR), KOR, MOR, respectively, as described previously (Obeng, Wilkerson et al., 2021). The binding assay at the opioid receptor subtypes was conducted using monoclonal opioid receptors expressed in Chinese hamster ovary cell lines for the DOR (a generous gift from Dr. Stephen J. Cutler, University of South Carolina) and MOR (PerkinElmer). The KORs (a generous gift from Dr. Stephen J. Cutler, University of South Carolina) were expressed in human embryonic kidney cells. The K_d and B_{max} values for the radioligands at each receptor subtype were first determined using a saturation assay (Supplementary Table 1). The Bradford protein assay was used to determine and adjust the concentration of protein required for the assay (Tal et al., 1985). Ten micrograms of each membrane protein was separately incubated with one of the radioligands in the presence of different concentrations of test compounds in Tris, $MgCl_2$, and ethylene glycol-bis(β -aminoethyl ether)- N,N,N',N' -tetraacetic acid [(50 mM Tris (Sigma-Aldrich), 3 mM $MgCl_2$ (Sigma-Aldrich), and 0.2 mM EGTA (Sigma-Aldrich), pH 7.7)] buffer for 60 minutes at room temperature. The bound radioligand was separated by filtration using the Connectorate filtermat harvester for 96-well microplates (Inotech, Dietikon, Switzerland) and counted for radioactivity using a MicroBeta2 microplate counter (PerkinElmer). Specific binding at each $A_{\alpha}R$ subtype was determined as the difference in binding obtained in the absence and presence of 10 μM lofexidine (Supplementary Table 1). Specific binding at the DOR, KOR, and MOR was determined as the difference in binding obtained in the absence and presence of 10 μM (+)-4-[(αR)- α -(2*S*,5*R*)-4-allyl-2,5-dimethyl-1-piperazinyl]-3-methoxybenzyl]- N,N -diethylbenzamide, U69,593, and naltrexone, respectively.

Subjects

Adult female and male Sprague Dawley rats at 10 weeks old upon arrival (Taconics, Germantown, NY; $n = 4$ per sex) were housed individually and acclimated for at least three days to a temperature- ($21.9^\circ C \pm 1.9^\circ C$) and humidity-controlled ($53\% \pm 14\%$) vivarium with a 12-hour light/dark cycle (lights on at 7:00 a.m. EST in the daylight saving time period) during which food (2918 Teklad global 18% protein rodent diets, Envigo, Frenchtown, NJ) and reverse osmosis water were available at all times. After the acclimation period, individual body weights were maintained at no less than 85% of free-feeding body weight as well as no less than 2.5 of the Body Conditioning Score (Ullman-Culleré and Foltz, 1999) by adjusting daily food rations. The free-feeding body weight was redetermined as requested by the veterinary staff at University of Florida. Access to chow (Dustless Precision Pellets Grain-Based Rodent Diet, Bio-Serv, Frenchtown, NJ) was provided in the rats' home cages approximately 30 minutes following daily experimental sessions. In addition to chow consumption, rats consumed a maximum of fifty 45-mg sucrose pellets (Dustless Precision Pellets 45 mg, Sucrose, Bio-Serv) available during experimental sessions for schedule-controlled responding as described in the following text. The animal protocol was approved by the Institutional Animal Care and Use Committee at the University of Florida and was in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.

Apparatus

The apparatus and procedures for the operant-conditioning and hotplate experiments were as previously described (Hiranita et al., 2019; Wilkerson et al., 2019; Obeng, Wilkerson et al., 2021).

Operant Conditioning Apparatus. Eight operant-conditioning chambers (Model ENV-008; Med Associates Inc., Fairfax, VT) were used, each enclosed within a sound-attenuating cubicle equipped with a fan for ventilation and white noise to mask extraneous sounds. On the front wall of each chamber were two retractable, 5-cm-long response levers, 5 cm from the midline and 9 cm above the grid floor. A response was defined as a downward displacement of the right lever with a force approximating 0.20 N whereas the left lever was not used. Two amber light-emitting diodes (LEDs) were aligned horizontally above two levers (one LED/lever); however, only the right LED and lever were activated for the correct study. A receptacle for the delivery of 45-mg sucrose pellets (Dustless Precision Pellets 45 mg, Sucrose, Bio-Serv) via a pellet dispenser (Model ENV-203-20; Med Associates Inc.) was mounted on the midline of the front wall between the levers and 2 cm above the floor. Each operant conditioning chamber was connected to a Dell desktop computer (Intel Core i7-7700 3.60 GHz processor, 16.0 GB of RAM, Microsoft Windows 10) through an interface (MED-SYST-8, Med Associates Inc.). Med-PC software version V (Med Associates Inc.) controlled experimental events and recorded responses. The chamber assignments remained the same for each subject throughout the study.

Hotplate. A square plate (Hot Plate Analgesia Meter, 1440 Analgesia Hot Plate with RS-232 Port and Software, Columbus Instruments, Columbus, OH) was surrounded by a clear acrylic cubicle with a lid. The stability of temperature on the plate surface was verified at $52^\circ C \pm 0.1^\circ C$ 30 minutes prior to each use.

Rectal Thermometer. An uninsulated microprobe (50313 Rat Rectal Probe, Stoelting, Wood Dale, IL) and a digital thermometer (50315 Body Temperature Thermometer, Stoelting) were used to measure rectal temperature. Veterinary ophthalmic ointment (Puralube, Dechra Veterinary Products, Overland Park, KS) was applied to the tip of the microprobe prior to each use.

In Vivo Procedures

The temperature, humidity, and light/dark cycle in the experimental room were equivalent to those in the vivarium. After the acclimation period to the vivarium, schedule-controlled responding experiments were conducted in the light cycle (8:00 a.m. to 11:00 a.m. E.S.T. in the daylight-saving time period) at the same time each day seven days per week. On drug test days, temperature and hotplate experiments were also conducted in that order (Fig. 1). Prior to the start of each daily experiment, body weight was measured. The sample size of each experimental group per treatment was eight using a within-subject design ($n = 4$ per sex). The doses of each test compound per injection were incremented sequentially at approximately 20-minute intervals (Fig. 1).

Within-Session, Six-Cycle Schedule-Controlled Responding. *Lever-response shaping.* Each experimental session commenced by placing an experimental subject in an individually assigned chamber daily up to 120 minutes. Each session started with the presentation of the right retractable

Rectal Temperature (RT), Hotplate (HP), and Schedule-Controlled Responding (SCR)




Fig. 1. Schematic presentation of experimental timelines on test and intertest sessions. The rate-decreasing, hypothermic, and antinociceptive effects of test compounds were repeatedly assessed in eight rats (four rats per sex) by measuring schedule-controlled responding (SCR) for presentation of food pellets, rectal temperature (RT), and hotplate (HP) response latency, respectively. RT and HP response latency were measured manually in this order only on test days. RT was measured using a microprobe. HP response latency was measured by placing each rat on a heated hotplate at 52°C and using a stopwatch. The experimental session consisted of six 20-minute experimental cycles and lasted for 120 minutes. On the test days, baseline values of RT and HP response latency were measured before the experimental session. After each rat received an injection (intraperitoneally, orally by gavage, or subcutaneously; T = 0 minutes), the first experimental cycle commenced by placing the rat in the operant-conditioning chamber. Each experimental cycle consisted of the 15-minute timeout period and then a 5-minute period for data collection of lever-pressing responses for presentations of food pellets using an automated system. Immediately following each 20-minute cycle, RT and HP response latency were measured in this order. Then, each rat received an injection of a dose of test compound, and the second cycle commenced by placing the rat in the operant-conditioning chamber. Doses of each test compound were administered cumulatively. The experimental procedures on intertest days were basically identical to those on test sessions. However, RT and HP response latency were not measured on intertest days. In addition, only the vehicle was administered on intertest days. The intertest sessions were conducted consecutively at least twice. See the Methods and Material section for more details.

lever and the illumination of the LED above the right lever. Each downward deflection of the right lever turned off the LEDs and activated the pellet dispenser for 0.1 seconds [fixed ratio (FR) 1 schedule] followed by a 0.1-second time-out period during which LEDs were turned off and responding had no scheduled consequences; the retractable lever remained presented during this time-out time. After 50 reinforcers per session were presented within 20 minutes for two consecutive sessions under the terminal FR10 schedule of reinforcement, and daily sessions were divided into multiple, discrete cycles.

Training. Each session consisted of six, 20-minute cycles with each cycle consisting of a 15-minute pretest phase and a 5-minute test phase in the operant-conditioning chambers (Fig. 1). Immediately prior to each cycle, vehicle was injected

intraperitoneally, and each animal was placed in the assigned chamber. Upon commencement of each session and at the beginning of each pretest phase, the right response lever was extended into the chamber, but the stimulus light remained off. Responses on the lever had no scheduled consequences. Upon commencement of each test phase of the cycle, the stimulus light was illuminated. Thereafter, all the experimental variables for the stimulus changes and response time-out conditions under the FR10 schedule of reinforcement were identical to those for response shaping except that the maximal number of food reinforcers delivered was fixed at 10 per cycle. When 10 food reinforcers were delivered during each test phase, the stimulus light was turned off and lever responding had no scheduled consequences. Upon completion of the last test

phase, the lever was retracted, and the stimulus light was turned off. Then, each animal was placed back to their home cages. Training continued until overall response rates (responses per second) across six cycles for two consecutive sessions were stably maintained with less than 25% variation, as determined per individual subject.

Testing. All the experimental variables were identical to those for the training period. However, a dose of a test compound was also injected per cycle other than vehicle. The first injection received was either vehicle or the pretreatment compound (i.e., antagonists naltrexone or yohimbine). The subsequent five injections were either vehicle or test compound. Each test compound was dosed cumulatively such that each dose per cycle was a subtraction from a summation of all the previous doses administered to achieve the target dose. The doses of the compounds administered (mg/kg) increased by either quarter or half log unit increments. Each test session was separated by a minimum of 72 hours and was studied with a nonsystematic order of compounds and doses. During the intertest maintenance sessions, all the experimental variables were identical to those for the training period, without any determination of the hotplate latency and rectal temperature as described next. Vehicle was injected at the beginning of each pretest phase.

Among food-maintained behavior, hotplate response latency, and rectal temperature, only analyses of food-maintained behavior allowed us to determine ED_{50} values of all the reference agonists at MOR, KOR, and A_{2R} (see Data Analysis). For the combinations of reference agonists, the cumulative doses in quarter log units in the mixtures per animal were determined based on the ED_{50} values of the rate-decreasing effects of reference agonist alone (Table 1), (Wilkerson et al., 2019). To determine the pharmacological influence of each drug on the observed effects, three ED_{50} ratios of drug mixtures were used. The order of testing was determined randomly. All dose-effect functions for drug mixtures were singly determined.

Hotplate and Rectal Temperature. On drug test days, the microprobe tip was inserted approximately 2.0-cm into each subject's rectum, and individual baseline temperature was measured within 10 seconds. Immediately after the baseline measurement of rectal temperature, each subject was manually placed on the heated plate, and baseline hotplate response latency was determined manually using a stopwatch (Martin Stopwatch, Martin Sports, Carlstadt, NJ) by trained and experimentally blinded raters. Hotplate response latency was measured until the subject jumped, licked or shook the back paws, or up to 60 seconds to avoid tissue damage, whichever occurred first.

Immediately following the determination of the baseline values, each subject underwent an injection of a dose of a test compound or vehicle and was placed in their respective operant conditioning chamber. Immediately after each cycle of the schedule-controlled responding experiment (cycles 1–6), rectal temperature and hotplate response latency were measured followed by an injection of a dose of the test compound or vehicle in this order.

Data Analysis

The dependent variables in each figure are shown as mean values \pm S.E.M. Mean and S.E.M. values per group of eight subjects were calculated as a function of compound doses,

cycles, or dose ratios of combined compounds. Statistical analyses were conducted using GraphPad Prism version 9 for Windows (GraphPad Software, Inc., San Diego, CA), SigmaPlot version 14.0 (Systat Software Inc., San Jose, CA), or R-4.1/RStudio Desktop (R Core Team, 2017). Comparisons were considered significant when a P value < 0.05 . A one-, two-, or three-way (repeated-measures) ANOVA followed by post hoc Bonferroni t tests was used as appropriate to analyze the effects of the compound dose, cycle, sex, dose ratio, or tolerance (assessment order: first or last dose-effect assessment for morphine, U69,593, and lofexidine) (Supplementary Fig. 2; Supplementary Tables 5–7). For the three-way repeated measures ANOVA, GraphPad Prism software was used for all 2×2 by X design, and the RStudio Desktop software was used for all others.

For rectal temperature and hotplate latency, each mean baseline value was determined per animal from all the baseline values determined on the drug sessions used in the following analyses. Hotplate latency values were converted to percent maximum possible antinociceptive effect (%MPE) with the following equation: $(100 \times ((\text{experimental test latency value} - \text{the averaged baseline latency value}) / (60 \text{ seconds} - \text{the averaged baseline latency value})))$. Changes in rectal temperature were calculated individually as the test value subtracted from the averaged baseline value. Rates of responding maintained by presentations of food pellets (responses/second) were expressed as a percentage of control, defined as the mean baseline rates across six daily cycles during all sessions one day prior to each test session. There was no increased or decreased trend for either hotplate latency, rectal temperature, or response rate baseline values (P values > 0.05). The dose-effect functions of morphine, U69,593, and lofexidine were determined twice, once at the start and once at the end of the within-subjects drug assessments. Only when the mean effect of a compound to reduce schedule-controlled responding or to increase %MPE was $> 50\%$ of maximum effects were the ED_{50} and slope values calculated using multiple linear regression (Snedecor and Cochran, 1967) and GraphPad Prism version 9 for Windows (GraphPad Software), where slopes were allowed to vary (Tallarida, 2000). Because only α_2R agonists produced $\geq 2^\circ\text{C}$ hypothermia, $ED_{2^\circ\text{C}}$ values were also individually calculated to compare the hypothermic potency. Only points on the linear part of the ascending (%MPE) and descending (response rate and rectal temperature) limbs of the dose-effect functions were used. If the 95% confidence intervals (CIs) of the ED_{50} , $ED_{2^\circ\text{C}}$, and slope values did not overlap or the potency or slope ratio of the compound alone or in combination with another compound did not include 1, potencies or slopes of the compounds were deemed statistically different. Among food-maintained behavior, hotplate response latency, and rectal temperature, only analyses of food-maintained behavior allowed us to determine ED_{50} values of all the reference agonists at MOR, KOR, and A_{2R} . For the mixture studies, the cumulative doses in quarter log units in the mixtures per animal were determined based on the ED_{50} values of the rate-decreasing effects of reference agonist alone (Wilkerson et al., 2019). That is, a within-subjects design was used, and each subject received dose combinations that were equivalent to the dose ratio based upon the individual ED_{50} of a drug to decrease response rates in that subject. The theoretical additive ED_{50} value of the combined drugs was calculated from the individual dose-effect functions to determine synergistic, additive, or subadditive interactions as previously described (Wilkerson et al., 2016, 2017, 2019). The combination was assumed to equal the sum of the effects of each drug. The

TABLE 1

Inhibition of binding of the radioligands labeling A α 2R and opioid receptor subtypesValues are K_i values for displacement of the radioligands (see Supplementary Table 1). Values in parentheses are 95% CIs unless noted. Values listed from previous studies were also added as reference.

Compound	A α _{2A} R K _i Value (nM)	A α _{2C} R K _i Value (nM)	DOR K _i Value (nM)	KOR K _i Value (nM)	MOR K _i Value (nM)	A α _{2C} /A α _{2A}	A α _{2A} /MOR	A α _{2C} /MOR
Clonidine	5.97 (3.66, 10.4)	60.8 (33.7, 115)	No inhibition up to 10 μ M	No inhibition up to 10 μ M	No inhibition up to 10 μ M	10.2	NA	NA
7-OH-MG	No inhibition up to 10 μ M	No inhibition up to 10 μ M	243 (168, 355)	220 (162, 302)	77.9 (45.8, 152)	NA	NA	NA
Lofexidine	1.21 (0.60, 2.43)	7.62 (3.96, 14.8)	No inhibition up to 10 μ M	No inhibition up to 10 μ M	No inhibition up to 10 μ M	6.30	NA	NA
Methadone	No inhibition up to 10 μ M	No inhibition up to 10 μ M	No inhibition up to 10 μ M	481 (294, 816)	6.61 (5.27, 8.32)	NA	NA	NA
MG	4,420 (2,720, 7,670) ^a 4,720 (S.E.M.: 120) ^b 2.3 μ M ^c	4,040 (1,880, 6,820) ^a 2,320 (S.E.M.: 140) ^b 3.5 μ M ^c	6,800 (2,980, 15,900) ^a	1,700 (1,090, 2,710) ^a	709 (451, 1,130) ^a	0.914	6.23	5.70
Morphine	No inhibition up to 10 μ M	No inhibition up to 10 μ M	250 (177, 346) ^a	40.4 (23.7, 70.9) ^a	4.19 (2.03, 11.1) ^a	NA	NA	NA
Naltrexone	No inhibition up to 10 μ M	No inhibition up to 10 μ M	37.2 (26.3, 53.0) ^a	1.19 (0.803, 1.79) ^a	1.84 (1.14, 3.03) ^a	NA	NA	NA
U69,593	No inhibition up to 10 μ M	No inhibition up to 10 μ M	6,700 (2,160, 28,000) ^a	1.62 ^a (1.02, 2.64) ^a	3,180 (1,050, 11,600) ^a	NA	NA	NA
Yohimbine	8.24 (5.40, 12.8)	7.77 (4.76, 12.8)	No inhibition up to 10 μ M	No inhibition up to 10 μ M	No inhibition up to 10 μ M	0.943	NA	NA

K_i, Inhibition constant. NA, Not applicable.^aHuman recombinant Chinese hamster ovary cells using [³H]2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole conducted at Eurofins Cerep (Celle l'Évescault, France) (Obeng et al., 2020).^bBinding at human opioid receptor cell lines (Obeng et al., 2021b).^cBinding at adrenergic receptors (A α _{2A} and A α _{2C}) conducted at the National Institute of Mental Health Psychoactive Drug Screening Program (NIMH, PDSP) (Ellis et al., 2020).

experimentally derived ED₅₀ values (Z_m) from the dose-effect functions of the ratios were compared with the predicted additive ED₅₀ values (Z_{add}) via a Fisher's exact test (Wilkerson et al., 2016, 2017, 2019). If the empirically derived value and the theoretical value did not significantly differ, the interaction was considered additive (Tallarida, 2001, 2006). For the in vitro studies, the assays were conducted in triplicate and repeated at least three times, and the IC₅₀ values were determined using a nonlinear, least-squares regression analysis (Prism 9; GraphPad Software, Inc.) and then converted to the inhibition constant (K_i) values using the Cheng–Prusoff equation (Cheng and Prusoff, 1973). The 95%CI (asymptotic) was calculated using Prism 9.

Results

Only the primary findings are shown here. Full details are described in the supplemental materials.

Receptor Binding

The K_i (nM) values of reference A α ₂R ligands clonidine, lofexidine, and yohimbine were 5.97, 1.21, and 8.24 at the A α _{2A}R, and 60.8, 7.62, and 7.77 at the A α _{2C}R, respectively (Table 1). The K_i values of reference A α ₂R ligands at opioid receptor subtypes and of reference opioid receptor ligands (methadone, morphine, naltrexone, and U69,593) at A α ₂R subtypes were not determined due to lack of inhibition up to 10 μ M (Table 1). The K_i values of MG were 4420 and 4040 nM at the A α _{2A}R and A α _{2C}R, respectively, whereas those of 7-OH-MG at these receptors were not determined due to lack of inhibition up to 10 μ M. Both MG and 7-OH-MG had higher affinities at the MOR than at the DOR and KOR; however, 7-OH-MG had a nine-fold higher affinity at the MOR than MG (Fig. 2; Table 1). A

summary of scintillation counting conditions employed for assessing affinity at various binding sites in competition for the radioligands labeling human A α ₂R and opioid receptor subtypes can be found in Supplementary Table 1.

Reference MOR Agonists Alone

Repeated vehicle injections did not alter response rates, rectal temperature, or nociceptive responding (Supplementary Fig. 1; Supplementary Tables 2 and 3). Morphine dose-dependently and significantly decreased response rates and rectal temperature, as well as produced antinociception (Fig. 3, upper panels, upward triangles; Supplementary Table 4). The ED₅₀ values of morphine to decrease response rates and to produce antinociception are shown in Table 2. The potency of morphine to produce the rate-decreasing effects was fourfold more potent than that for antinociception (Table 2).

Methadone significantly decreased response rates and rectal temperature and produced antinociception (Fig. 3, upper panels, downward triangles; Supplementary Tables 4 and 5). Relative to morphine, methadone was 7- and fivefold more potent to produce rate-decreasing and antinociceptive effects, respectively (Table 2).

Reference KOR Agonist Alone

U69,593 significantly decreased response rates and rectal temperature and produced antinociception (Fig. 3, upper panels, circles; Supplementary Table 6). Relative to morphine, U69,593 was two- and fourfold more potent to produce the rate-decreasing and antinociceptive effects, respectively (Table 2). U69,593 was equipotent to decrease response rates and produce antinociception, as measured by increased %MPE (Table 2).




Fig. 2. Displacement of radioligands at opioid receptor and A_{2R} subtypes. Ordinates: percentage of specific radiotracer bound to membrane preparations. Abscissae: concentrations of each competing compound (log scale). Each data point represents the mean results of three repeated experiments; vertical bars represent S.E.M. ($n = 3$) from at least three independent triplicate replications per sample. K_i and 95% CI values from curve-fitting analyses of these data are shown in Table 1. Note that affinity of MG at the MOR and A_{2R} was approximately equal whereas no considerable affinity of 7-OH-MG was found at the A_{2R} .

There was no significant change in potency across the rates of responding, antinociception, or rectal temperature (Table 2; Supplementary Fig. 2; Supplementary Table 6).

Reference A_{2R} Agonists Alone

Lofexidine significantly decreased response rates and rectal temperature and significantly increased %MPE; the antinociceptive effects of lofexidine reached statistical significance, but the maximum effects of lofexidine were a mean of 17.3% and significantly less than those of reference MOR agonists ($F_{1,6} = 361$, $P < 0.001$, two-way repeated measures ANOVA) (Fig. 3, upper panels, diamonds; Supplementary Table 7). In contrast, as compared with the reference MOR agonists, the hypothermic effects of lofexidine were significantly greater (e.g., 4.1°C decrease in rectal temperature at 0.56 mg/kg) (Fig. 3). Lofexidine was 38-fold more potent than morphine to produce the rate-decreasing effects (Table 2). The potency of lofexidine to reduce response rates was threefold greater than its potency to decrease rectal temperature (Table 2).

Clonidine significantly decreased response rates and rectal temperature; however, statistically significant antinociception was not obtained (Fig. 3, upper panels, squares; Supplementary Table 7). Clonidine was four- and threefold more potent than lofexidine to produce the rate-decreasing and hypothermic effects, respectively (Table 2). The potency of clonidine to produce the rate-decreasing effects was fourfold more potent than that for the hypothermic effects (Table 2).

MG and 7-OH-MG Alone

When administered intraperitoneally, MG significantly decreased response rates; however, neither statistically significant antinociception nor altered rectal temperature was obtained (Fig. 3, lower panels, circles; Supplementary Table 8). MG (intraperitoneally) was fourfold more potent than intraperitoneal morphine to produce the rate-decreasing effects (Table 2). MG had been expected to produce antinociceptive and hypothermic effects because other effects produced by MG

are antagonized by MOR and A_{2R} antagonists (Foss et al., 2020; Obeng, Wilkerson et al., 2021). Thus, the route of administration of MG was varied, and the effects of 7-OH-MG, an active metabolite of MG at the MOR, were assessed.

Both oral and subcutaneous MG significantly decreased rates of responding, and no significant antinociception was observed; there were relatively small yet significant increases in rectal temperature (Fig. 3, lower panels, downward and upward triangles, respectively; Supplementary Table 8). MG administered orally by gavage and subcutaneously was three- and sixfold less potent, respectively, than intraperitoneal MG to produce the rate-decreasing effects (Table 2).

In contrast to MG, intraperitoneal 7-OH-MG significantly decreased response rates and produced hot plate antinociception; however, no significant effects on rectal temperature were obtained (Fig. 3, lower panels, squares; Supplementary Table 8). The potency of 7-OH-MG to reduce response rates was approximately fourfold more potent than its potency to produce antinociception (Table 2).

Reference MOR Agonists in Combination with Naltrexone or Yohimbine

By themselves, naltrexone (0.032, 1 mg/kg i.p.) and yohimbine (1, 3.2 mg/kg i.p.), did not alter food-maintained behavior, antinociception, or rectal temperature (Supplementary Fig. 3; Supplementary Table 9). Naltrexone dose-dependently and significantly shifted to the right the dose-effect functions of the rate-decreasing and antinociceptive effects of morphine (Fig. 4; Table 2; Supplementary Table 4). The lower dose of naltrexone (0.032 mg/kg) produced significant antagonism of the rate-decreasing and antinociceptive effects of morphine (Table 2). Yohimbine (3.2 mg/kg) did not significantly change the effects of morphine on rates of responding, antinociception, or changes in rectal temperature (Fig. 4; Table 2; Supplementary Table 4).




Fig. 3. The rate-decreasing, antinociceptive, and hypothermic effects of various compounds alone in rats. Abscissae: Vehicle and cumulative dose of compound in mg/kg (log scale). Ordinates: *Left panels*, percentage of mean rates of responding after repeated administration of vehicle during intertest sessions; *middle panels*, percentage of %MPE in the hotplate assay; *right panels*, changes in rectal temperature from mean baselines. Each point represents the mean \pm S.E.M. ($n = 4$ per sex per data point). All compounds were administered intraperitoneally 15 minutes before each 5-minute period for data collection for food-maintained behavior, and MG was also administered orally by gavage and subcutaneously (lower panels). The data for morphine, U69,593, and lofexidine on the first assessment were plotted. *Upper left:* The rate-decreasing effects of vehicle, the reference MOR agonists (morphine and methadone), reference α_2 R agonists (lofexidine and clonidine), and reference KOR agonist U69,593. Filled circles represent repeated vehicle (intraperitoneal) administration. Morphine dose (intraperitoneal, upward triangles); vehicle, 5.6, 10, 17.8, 32, and 56 mg/kg. Methadone dose (intraperitoneal, downward triangles); vehicle, 0.32, 0.56, 1.0, 1.78, and 3.2 mg/kg. Lofexidine doses (intraperitoneal, diamonds); vehicle, 0.056, 0.1, 0.178, 0.32, and 0.56 mg/kg. Clonidine doses (intraperitoneal, squares); vehicle, 0.0178, 0.032, 0.056, 0.1, and 0.178 mg/kg. U69,593 doses (intraperitoneal, open circles); 0.56, 1.0, 1.78, 3.2, and 5.6 mg/kg. *Upper middle:* The antinociceptive effects of reference compounds. *Upper right:* The hypothermic effects of reference compounds. *Lower left:* The rate-decreasing effects of MG and 7-OH-MG. MG dose (intraperitoneal, circles); vehicle, 5.6, 10, 17.8, 32, and 56 mg/kg. MG dose (orally by gavage, circles); vehicle, 17.8, 32, 56, 100, and 178 mg/kg. MG dose (subcutaneously, triangles); vehicle, 17.8, 32, 56, 100, and 178 mg/kg. 7-OH-MG dose (intraperitoneal, squares); vehicle, 0.32, 1.0, 3.2, 10, and 32 mg/kg. *Lower middle:* The antinociceptive effects of MG and 7-OH-MG. *Lower right:* The hypothermic effects of MG and 7-OH-MG. Each gray symbol indicates a significant difference from vehicle per corresponding cycle. Note that all test compounds decreased food-maintained behavior. Robust antinociception was produced by the reference α_2 R agonists but not by the reference MOR agonists whereas robust hypothermia was produced by the reference α_2 R agonists but not by the reference MOR agonists. Regardless of the route of administration, MG did not produce robust antinociception or hypothermia. As with the reference MOR agonists, 7-OH-MG produced robust antinociception but did not produce significant hypothermia.

Naltrexone (0.032 mg/kg) produced a fivefold rightward shift of the methadone rate-decreasing dose-effect function (Fig. 4; Table 2; Supplementary Table 4). Yohimbine (3.2 mg/kg) did not significantly modify the effects of methadone on rates of responding, antinociception, or changes in rectal temperature (Fig. 4; Table 2; Supplementary Table 4).

U69,593 in Combination with Naltrexone or Yohimbine

Naltrexone (0.032 mg/kg) produced a small but statistically significant leftward shift of the U69,593 rate-decreasing dose-effect function but did not modify U69,593 antinociceptive or hypothermic effects (Fig. 4; Table 2; Supplementary Table 6). Naltrexone (1.0 mg/kg) significantly antagonized

TABLE 2

ED50 and E-2C° values in mg/kg for the rate-decreasing, antinociceptive, hypothermic effects of various compounds as shown in Figs. 3 to 6 and Supplementary Figs. 2 to 4. The sample sizes are described in each figure legend. Each value is a combination of females and males unless otherwise noted. Potency ratios (S.E.M.s) are calculated by dividing the ED50 or E-2C° values for producing the antinociceptive or hypothermic effects, respectively, and by the ED50 values for producing the rate-decreasing effects. Values in parentheses are 95% CIs. Significant differences are bold.

Combination	Morphine Dose		Potency Ratio		
	Decrease in Response Rate (ED ₅₀)	ED ₅₀ or E _{2C'} (S.E.M.)	Hypothermia (E _{2C'})	Antinociception/Decrease in Response Rate	Hypothermia/Decrease in Response Rate
Morphine dose					
Morphine alone	9.81 (7.32, 12.30)	39.30 (37.18, 41.43)	NA	4.00 (3.02, 5.66)	NA
Morphine + 0.032 mg/kg naltrexone	43.8 (41.6, 46.0)	210 (188, 232)	NA	4.79 (4.09, 5.58)	NA
Morphine + 1.0 mg/kg naltrexone	309 (257, 361)	NA	NA	NA	NA
Morphine + 3.2 mg/kg yohimbine	13.5 (11.1, 15.9)	24.3 (19.0, 29.6)	NA	1.80 (1.20, 2.67)	NA
Morphine + 17.8 mg/kg MG	9.29 (6.55, 12.03)	35.9 (33.8, 38.0)	NA	3.86 (2.81, 5.80)	NA
Morphine + 0.32 mg/kg 7-OH-MG	19.5 (15.8, 23.2)	33.1 (29.6, 36.6)	NA	1.70 (1.28, 2.32)	NA
Methadone dose					
Methadone alone	0.70 (0.48, 0.92)	2.22 (1.74, 2.70)	NA	3.17 (1.89, 5.63)	NA
Methadone + 0.032 mg/kg naltrexone	2.87 (2.65, 3.09)	25.3 (24.3, 26.3)	NA	8.81 (7.86, 9.92)	NA
Methadone + 3.2 mg/kg yohimbine	1.19 (1.00, 1.40)	2.28 (1.80, 2.76)	NA	1.91 (1.29, 2.76)	NA
Methadone + 17.8 mg/kg MG	1.04 (0.92, 1.16)	2.25 (2.05, 2.45)	NA	2.16 (1.77, 2.66)	NA
Methadone + 0.32 mg/kg 7-OH-MG	1.16 (0.86, 1.50)	1.93 (1.86, 2.00)	NA	1.66 (1.24, 2.33)	NA
U69,593 dose					
U69,593 alone	2.17 (1.70, 2.65)	3.17 (2.39, 3.95)	NA	1.46 (0.90, 2.32)	NA
U69,593 + 0.032 mg/kg naltrexone	NA	1.86 (1.52, 2.20)	NA	NA	NA
U69,593 + 1.0 mg/kg naltrexone	14.58 (11.87, 17.29)	49.07 (47.0, 51.20)	NA	3.36 (2.72, 4.31)	NA
U69,593 + 3.2 mg/kg yohimbine	2.28 (1.80, 2.80)	2.62 (1.84, 3.40)	NA	1.15 (0.657, 1.89)	NA
U69,593 + 17.8 mg/kg MG	3.10 (2.74, 3.46)	4.66 (4.15, 5.17)	NA	1.50 (1.19, 1.89)	NA
U69,593 + 0.32 mg/kg 7-OH-MG	5.61 (4.67, 6.55)	16.0 (15.0, 16.9)	NA	2.85 (2.29, 3.62)	NA
Lofexidine dose					
Lofexidine alone	0.153 (0.121, 0.185)	NA	0.294 (0.267, 0.321)	NA	1.92 (1.44, 2.65)
Lofexidine + 1.0 mg/kg naltrexone	0.107 (0.085, 0.129)	NA	0.395 (0.332, 0.458)	NA	3.69 (2.57, 5.39)
Lofexidine + 1.0 mg/kg yohimbine	0.788 (0.683, 0.893)	NA	1.06 (0.887, 1.23)	NA	1.35 (0.993, 1.80)
Lofexidine + 3.2 mg/kg yohimbine	1.89 (1.60, 2.18)	NA	3.69 (2.84, 4.54)	NA	1.95 (1.30, 2.84)
Lofexidine + 17.8 mg/kg MG	0.019 (0.014, 0.024)	0.168 (0.161, 0.175)	0.037 (0.027, 0.046)	8.84 (6.71, 12.5)	1.95 (1.13, 3.29)
Lofexidine + 0.32 mg/kg 7-OH-MG	NA	0.472 (0.457, 0.487)	0.208 (0.181, 0.235)	NA	NA
Clonidine dose					
Clonidine alone	0.048 (0.038, 0.058)	NA	0.094 (0.088, 0.100)	NA	1.96 (1.52, 2.63)
Clonidine + 1.0 mg/kg naltrexone	0.054 (0.044, 0.064)	NA	0.105 (0.087, 0.123)	NA	1.94 (1.36, 2.80)
Clonidine + 1.0 mg/kg yohimbine	0.186 (0.159, 0.213)	NA	0.544 (0.474, 0.614)	NA	2.92 (2.23, 3.86)
Clonidine + 17.8 mg/kg MG	NA (no more than 50% data point)	0.042 (0.039, 0.186)	0.0633 (0.0501, 0.045)	NA	NA
Clonidine + 0.32 mg/kg 7-OH-MG	NA (no more than 50% data point)	NA (up to 47.5% MPE)	0.093 (0.089, 0.097)	NA	NA
MG dose					
MG alone (i.p.)	27.2 (21.0, 33.4)	NA	NA	NA	NA
MG (i.p.) + 1.0 mg/kg naltrexone	33.8 (22.7, 45.0)	NA	NA	NA	NA
MG (i.p.) + 3.2 mg/kg yohimbine	32.0 (27.0, 37.0)	NA	NA	NA	NA
MG alone (p.o.)	89.3 (69.8, 108)	NA	NA	NA	NA
MG alone (s.c.)	161 (118, 204)	NA	NA	NA	NA

TABLE 2 continued

Combination	Morphine Dose		Potency Ratio	
	ED ₅₀ or E ₂₀ ^c (S.E.M.)		Antinociception/ Decrease in Response Rate	Hypothermia/ Decrease in Response Rate
	Decrease in Response Rate (ED ₅₀)	Antinociception (ED ₅₀)	Hypothermia (E ₂₀ ^c)	
7-OH-MG dose				
7-OH-MG alone	1.82 (1.22, 2.42)	9.13 (7.41, 10.9)	NA	NA
7-OH-MG + 0.032 mg/kg naltrexone	17.5 (14.4, 20.7)	41.8 (38.2, 45.5)	NA	NA
7-OH-MG + 3.2 mg/kg yohimbine	3.07 (2.53, 3.61)	15.7 (14.1, 17.3)	NA	NA

NA, not applicable.

the rate-decreasing, antinociceptive, and hypothermic effects of U69,593 (Fig. 4; Table 2; Supplementary Table 6). Naltrexone produced a five- and threefold, respectively, rightward shift of the U69,593 rate-decreasing and antinociceptive dose-effect function (Table 2). Yohimbine (3.2 mg/kg) did not modify U69,593-related rates of responding, antinociception, or rectal temperature (Fig. 4; Table 2; Supplementary Table 6).

Reference A α ₂R Agonists in Combination with Naltrexone or Yohimbine

Naltrexone did not modify the effects of lofexidine on rates of responding, hot plate antinociception, or rectal temperature (Fig. 4; Table 2; Supplementary Table 7). Yohimbine dose-dependently and significantly shifted to the right the dose-effect functions of the rate-decreasing and hypothermic effects of lofexidine (Fig. 4; Table 2; Supplementary Table 7). The lower dose of yohimbine (1.0 mg/kg) produced a fourfold shift to the right of the lofexidine dose-effect functions to decrease response rates and rectal temperature (Supplementary Table 7).

Naltrexone did not modify the effects of clonidine on rates of responding, antinociception, or rectal temperature (Fig. 4; Table 2; Supplementary Table 7). Yohimbine (1.0 mg/kg) produced an eight- and fourfold, respectively, rightward shift of the clonidine rate-decreasing and hypothermic dose-effect function (Fig. 4; Table 2; Supplementary Table 7).

MG (Intraperitoneal) and 7-OH-MG in Combination with Naltrexone or Yohimbine

Because the intraperitoneal route was most potent of the three routes of administration tested in decreasing the response rates, the intraperitoneal route was used to assess the pharmacological impact of naltrexone (1.0 mg/kg) or yohimbine (3.2 mg/kg) on MG-related behaviors and physiology. Neither naltrexone nor yohimbine significantly modified the dose-effect function of MG to decrease responding (Fig. 5; Table 2; Supplementary Table 8). Naltrexone (0.032 mg/kg) significantly shifted the dose-effect functions of 7-OH-MG threefold rightward for both rate-decreasing and antinociceptive effects (Fig. 5; Table 2; Supplementary Table 8). In contrast, yohimbine (3.2 mg/kg) did not significantly modify the rate-decreasing or antinociceptive 7-OH-MG dose-effect functions (Fig. 5, Table 2; Supplementary Table 8).

Reference Agonists in Combination with MG or 7-OH-MG

By themselves, MG (17.8 mg/kg i.p.) and 7-OH-MG (0.32 mg/kg i.p.) did not alter food-maintained behavior, antinociception, or rectal temperature (Supplementary Fig. 3; Supplementary Table 9). Pretreatment effects of behaviorally inactive doses of MG (17.8 mg/kg) or 7-OH-MG (0.32 mg/kg) were assessed on the effects of previously tested reference agonists to understand the interaction of MG or its metabolite with the reference agonists (Fig. 6). Neither MG nor 7-OH-MG significantly modified the rate-decreasing and antinociceptive dose-effect functions of morphine and methadone (Fig. 6; Table 2; Supplementary Table 4).

MG pretreatment did not significantly modify the rate-decreasing, antinociceptive and hypothermic dose-effect functions of U69,593 (Fig. 6; Table 2; Supplementary Table 6). 7-OH-MG did not significantly alter the dose-effect functions of rates of responding or rectal temperature for U69,593 whereas




Fig. 4. The rate-decreasing, antinociceptive, and hypothermic effects of reference agonists in the presence of naltrexone (NLT; opioid receptor antagonist) or yohimbine (YHM; α_2 R antagonist). Abscissae: Vehicle and cumulative dose of reference agonist in mg/kg (intraperitoneal, log scale). Ordinates: *Top row*, percentage of mean rates of responding after repeated administration of vehicle during intertest sessions; *middle row*, percentage of maximum possible effects in the hotplate assay; *bottom row*, changes in rectal temperature from mean baselines. Each point represents the mean \pm S.E.M. ($n = 4$ per sex per data point). Naltrexone and yohimbine were administered intraperitoneally immediately before each session, and all reference agonists were administered intraperitoneally 15 minutes before each 5-minute period for data collection for food-maintained behavior. Each data of compound alone (i.e., "None" in each figure key) was replotted from Figure 3. *Leftmost panels:* The effects of morphine. Morphine dose alone (filled circles) and in the presence of 3.2 mg/kg yohimbine (open squares); vehicle, 5.6, 10, 17.8, 32, and 56 mg/kg. Morphine dose in the presence of 0.032 mg/kg naltrexone (open upward triangles); vehicle, 17.8, 32, 56, 100, and 178 mg/kg. Morphine dose in the presence of 1.0 mg/kg naltrexone (open downward triangles); vehicle, 56, 100, 178, 320, and 560 mg/kg. *Second leftmost panels:* The effects of methadone. Methadone dose alone (filled circles) and in the presence of 3.2 mg/kg yohimbine (open squares); vehicle, 0.32, 0.56, 1.0, 1.78, 3.2, and 5.6 mg/kg. Methadone dose in the presence of 1.0 mg/kg naltrexone (open downward triangles); vehicle, 1.0, 1.78, 3.2, 5.6, and 10 mg/kg. *Third leftmost panels:* The effects of U69,593. U69,593 dose alone (filled circles) and in the presence of 0.032 mg/kg naltrexone (open upward triangles) or 3.2 mg/kg yohimbine (open squares); vehicle, 0.56, 1.0, 1.78, 3.2, and 5.6 mg/kg. U69,593 dose in the presence of 1.0 mg/kg naltrexone (open downward triangles); vehicle, 1.78, 3.2, 5.6, 10, and 17.8 mg/kg. *Fourth leftmost panels:* The effects of lofexidine. Lofexidine dose alone (filled circles) and in the presence of 1.0 mg/kg naltrexone (open downward triangles); vehicle, 0.056, 0.1, 0.178, 0.32, and 0.56 mg/kg. Lofexidine dose in the presence of 1.0 mg/kg yohimbine (diamonds); vehicle, and 0.178, 0.32, 0.56, 1.0, and 1.78 mg/kg. Lofexidine dose in the presence of 3.2 mg/kg yohimbine (open squares); vehicle, 0.56, 1.0, 1.78, 3.2, and 5.6 mg/kg. *Rightmost panels:* The effects of clonidine. Clonidine alone and in the presence of 1.0 mg/kg naltrexone (open downward triangles); vehicle, 0.0178, 0.032, 0.056, 0.1, and 0.178 mg/kg. Clonidine dose in the presence of 3.2 mg/kg yohimbine (open squares); vehicle, 0.056, 0.1, 0.178, 0.32, and 0.56 mg/kg. Each gray symbol indicates a significant difference from vehicle per corresponding cycle as shown in Fig. 3. Note that the lower dose of naltrexone antagonized the rate-decreasing and antinociceptive effects of the reference MOR agonists. The higher dose of naltrexone antagonized the rate-decreasing and antinociceptive effects of morphine and U69,593. The lower dose of yohimbine antagonized the rate-decreasing and hypothermic effects of the reference α_2 R agonists.

7-OH-MG produced a significant fourfold rightward shift in the U69,593 hotplate antinociception dose-effect function (Fig. 6; Table 2; Supplementary Table 6).

MG produced a leftward shift in both lofexidine and clonidine rate-decreasing and hypothermic effect dose-effect functions

(Fig. 6; Table 2; Supplementary Table 7). When combined with MG, lofexidine and clonidine produced significantly greater hotplate antinociception than either lofexidine alone or clonidine alone (Fig. 6; Table 2; Supplementary Table 7). The mean hotplate antinociceptive values, expressed as %MPE, of lofexidine




Fig. 5. The rate-decreasing, antinociceptive, and hypothermic effects of MG and 7-OH-MG in the presence of naltrexone (NLT: opioid receptor antagonist) or yohimbine (YHM; α_2 R antagonist). Abscissae: Vehicle and cumulative dose of test compound in mg/kg (intraperitoneal, log scale). Ordinates: *Top row*, percentage of mean rates of responding after repeated administration of vehicle during intertest sessions; *middle row*, percentage of maximum possible effects in the hotplate assay; *bottom row*, changes in rectal temperature from mean baselines. Each point represents the mean \pm S.E.M. ($n = 4$ per sex per data point). Naltrexone and yohimbine were administered intraperitoneally immediately before each session, and all other compounds were administered intraperitoneally 15 minutes before each 5-minute period for data collection for food-maintained behavior. Each data of test compound alone (i.e., "None" in each figure key) was replotted from Fig. 3. *Left panels*: The effects of MG. MG dose alone (filled circles) and in the presence of 1.0 mg/kg naltrexone (open downward triangles) or 3.2 mg/kg yohimbine (open squares); vehicle, 5.6, 10, 17.8, 32, and 56 mg/kg. *Right panels*: The effects of 7-OH-MG. 7-OH-MG dose alone (filled circles) and in the presence of 3.2 mg/kg yohimbine (open squares); vehicle, 0.32, 1.0, 3.2, 10, and 32 mg/kg. 7-OH-MG dose in the presence of .032 mg/kg naltrexone (open upward triangles); vehicle, 1.0, 3.2, 10, 32, and 56 mg/kg. Each gray symbol indicates a significant difference from vehicle per corresponding cycle as shown in Fig. 3. Note that each high dose of naltrexone and yohimbine did not significantly antagonize the rate-decreasing effects of MG. The lower dose of naltrexone antagonized the rate-decreasing and antinociceptive effects of 7-OH-MG.

alone and clonidine alone were $<20\%$ (Fig. 6). As with MG, 7-OH-MG shifted to the left the dose-effect functions of the rate-decreasing effects of lofexidine and clonidine and rendered lofexidine and clonidine antinociceptive (Fig. 6; Table 2; Supplementary Table 7). However, in contrast to MG, 7-OH-MG did not significantly modify either lofexidine or clonidine hypothermic dose-effect functions (Fig. 6; Table 2; Supplementary Table 7).

Combinations of the Reference Agonists

Among food-maintained behavior, hotplate response latency, and rectal temperature, only analyses of food-maintained behavior were used to determine the ED_{50} values of all the reference agonists at MOR, KOR, and α_2 R (Table 3). Based on the calculated rate decreasing ED_{50} values of each reference compound alone, doses for the mixtures in ED_{50} ratios of 3:1, 1:1, and 1:2 parts morphine to lofexidine were administered cumulatively in quarter log units (Table 3). Each drug combination produced dose-related decreases in response rates (Supplementary Fig. 4; Supplementary Table 10). Hotplate antinociception and hypothermia were also assessed. All morphine dose ratios produced similar leftward antinociceptive morphine dose-effect function shifts. As the morphine dose ratio increased (i.e., 1:2, 1:1, 3:1 morphine to lofexidine) the hypothermia dose-effect functions shifted further to the left (Supplementary Fig. 4; Supplementary Table 10). As the lofexidine dose ratio decreased (i.e., 1:2, 1:1, 3:1 morphine to lofexidine) the antinociception dose-effect functions shifted further to the left (Supplementary Fig. 4; Supplementary Table 10). All lofexidine dose ratios produced similar leftward lofexidine hyperthermic dose-effect function shifts.

We also examined, based upon the ED_{50} doses to decrease response rates, 2:1, 1:2, and 3:1 morphine to clonidine dose mixtures. Each drug combination produced dose-related decreases in response rates. We found similar shifts as seen with morphine and lofexidine, in the morphine and clonidine antinociceptive and hypothermia dose-effect relationships (Supplementary Fig. 5; Supplementary Table 10). A similar trend for inverse opioid and adrenergic receptor agonist antinociceptive and hypothermic dose-effect function shifts, based on the relative opioid to adrenergic receptor agonist dose ratio were also consistently observed with 1:2, 1:1, and 3:1 methadone to lofexidine (Supplementary Fig. 6; Supplementary Table 10); 4:1, 2:1, and 1:1 methadone to clonidine (Supplementary Fig. 7; Supplementary Table 10); 1:2, 1:1, and 2:1 U69,593 to lofexidine (Supplementary Fig. 8; Supplementary Table 10); and 1:2, 2:1, and 3:1 U69,593 to clonidine (Supplementary Fig. 9; Supplementary Table 10) ED_{50} ratios.

Interactive Effects of Reference Compounds

Subadditivity for drug combination rate decreasing effects was not observed in any of the previously discussed morphine to lofexidine, morphine to clonidine, methadone to lofexidine, methadone to clonidine, U69,593 to lofexidine, or U69,593 to clonidine drug combinations (Fig. 7; Table 4). Additive effects were generally observed, with a few exceptions where supra-additivity was found. Supra-additivity was observed under the following dose ratios 1:1 and 1:2 morphine to lofexidine; 2:1 and 1:2 morphine to clonidine; 2:1 methadone to clonidine; 1:1, 1:2, and 2:1 U69,593 to lofexidine; and 2:1 and 1:2 U69,593 to clonidine (Fig. 7; Table 4).

Discussion

In this study, we observed several novel findings. MG had comparable binding affinities at α_2 R and MOR whereas 7-OH-MG, an active metabolite of MG, had relatively high affinity at MOR and negligible affinity at α_2 R. Among three experimental assays employed in this study, we examined drug-drug schedule-




Fig. 6. The rate-decreasing, antinociceptive, and hypothermic effects of reference agonists in the presence of MG and 7-OH-MG. Abscissae: Vehicle and cumulative dose of reference agonist in mg/kg (intraperitoneal, log scale). Ordinates: *Top row*, percentage of mean rates of responding after repeated administration of vehicle during intertest sessions; *middle row*, percentage of maximum possible effects in the hotplate assay; *bottom row*, changes in rectal temperature from mean baselines. Each point represents the mean \pm S.E.M. ($n = 4$ per sex per data point). MG and 7-OH-MG were administered intraperitoneally immediately before each session, and all reference agonists were administered intraperitoneally 15 minutes before each 5-minute period for data collection for food-maintained behavior. Each data of reference agonists alone (i.e., "None" in each figure key) was re-plotted from Fig. 3. *Leftmost panels:* The effects of morphine. Morphine dose alone (filled circles) and in the presence of 17.8 mg/kg MG (open squares) or 0.32 mg/kg 7-OH-MG (open diamonds); vehicle, 5.6, 10, 17.8, 32, and 56 mg/kg. *Second leftmost panels:* The effects of methadone. Methadone dose alone (filled circles) and in the presence of 17.8 mg/kg MG (open squares) or 0.32 mg/kg 7-OH-MG (open diamonds); vehicle, 0.32, 0.56, 1.0, 1.78, and 3.2 mg/kg. *Third leftmost panels:* The effects of U69,593. U69,593 dose alone (filled circles) and in the presence of 17.8 mg/kg MG (open squares) or 0.32 mg/kg 7-OH-MG (open diamonds); vehicle, 0.56, 1.0, 1.78, 3.2, and 5.6 mg/kg. *Fourth leftmost panels:* The effects of lofexidine. Lofexidine dose alone (filled circles) and in the presence of 0.32 mg/kg 7-OH-MG (open diamonds); vehicle, 0.056, 0.1, 0.178, 0.32, and 0.56 mg/kg. Lofexidine dose in the presence of 17.8 mg/kg MG (open squares); vehicle, 0.0178, 0.032, 0.056, 0.1, and 0.178 mg/kg. *Rightmost panels:* The effects of clonidine. Clonidine alone and in the presence of 0.32 mg/kg 7-OH-MG (open diamonds); vehicle, 0.0056, 0.01, 0.0178, 0.032, and 0.056 mg/kg. Each gray symbol indicates a significant difference from vehicle per corresponding cycle as shown in Fig. 3. Note that MG potentiated the rate-decreasing and hypothermic effects of the reference A_{2R} agonists. In the presence of MG and 7-OH-MG, the reference A_{2R} agonists also produced relatively robust antinociception.

controlled responding interactions via isobolar analysis. MG and 7-OH-MG potentiated the rate-decreasing effects of A_{2R} agonists, but not MOR agonists, and increased the potency of A_{2R} agonists to produce antinociception. MG, but not 7-OH-MG, potentiated the hypothermic effects of the A_{2R} agonists. Neither naltrexone nor yohimbine antagonized the rate-decreasing effects of MG, whereas naltrexone, but not yohimbine, antagonized the rate-decreasing effects of 7-OH-MG. Thus, these isobolar analyses suggest that to produce the opioid-sparing effects of A_{2R} agonists a specific dose combination is required. In addition, these results suggest that MG and 7-OH-MG may produce antinociceptive

synergism with both A_{2R} and MOR agonists. Furthermore, MG, but not 7-OH-MG, when combined with A_{2R} agonists may produce hypothermic synergism.

The supra-additive interactions between MOR and A_{2R} on schedule-controlled responding was observed at various dose ratios (i.e., 2:1, 1:1, 1:2), and these interactive effects may be specific to schedule-controlled responding. For example, in several mouse and rat antinociception studies, others have found supra-additive interactions between MOR and A_{2R} only when mixtures included low proportions of the MOR agonist relative to an A_{2R} agonist based on their individual potencies

TABLE 3

Cumulative doses of test compounds (mg/kg) studied in compound mixtures
Values in parentheses are S.E.M.

Compound	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6
1 Morphine: 1 Lofexidine						
Morphine	Vehicle	1.79 (0.447)	3.19 (0.795)	5.69 (1.42)	10.1 (2.52)	18.0 (4.48)
Lofexidine	Vehicle	0.0196 (0.00433)	0.0348 (0.00771)	0.0620 (0.0137)	0.110 (0.0244)	0.196 (0.0435)
1 Morphine: 2 Lofexidine						
Morphine	Vehicle	0.897 (0.223)	1.60 (0.398)	2.84 (0.708)	5.06 (1.26)	9.01 (2.24)
Lofexidine	Vehicle	0.0293 (0.00650)	0.0522 (0.0116)	0.0930 (0.0206)	0.165 (0.0367)	0.295 (0.0652)
3 Morphine: 1 Lofexidine						
Morphine	Vehicle	2.69 (0.670)	4.79 (1.19)	8.53 (2.12)	15.2 (3.78)	27.0 (6.73)
Lofexidine	Vehicle	0.00978 (0.00217)	0.0174 (0.00386)	0.0310 (0.00686)	0.0552 (0.0122)	0.0982 (0.0217)
2 Morphine: 1 Clonidine						
Morphine	Vehicle	1.79 (0.447)	3.19 (0.795)	5.69 (1.42)	10.1 (2.52)	18.0 (4.48)
Clonidine	Vehicle	0.00379 (0.000994)	0.00675 (0.00177)	0.0120 (0.00315)	0.0214 (0.00561)	0.0381 (0.00998)
1 Morphine: 2 Clonidine						
Morphine	Vehicle	0.897 (0.223)	1.60 (0.398)	2.84 (0.708)	5.06 (1.26)	9.01 (2.24)
Clonidine	Vehicle	0.00569 (0.00149)	0.0101 (0.00266)	0.0180 (0.00473)	0.0321 (0.00841)	0.0571 (0.0150)
3 Morphine: 1 Clonidine						
Morphine	Vehicle	2.69 (0.670)	4.79 (1.19)	8.53 (2.12)	15.2 (3.78)	27.0 (6.73)
Clonidine	Vehicle	0.00190 (0.000497)	0.00338 (0.000885)	0.00601 (0.00158)	0.0107 (0.00280)	0.0190 (0.00499)
1 Methadone: 1 Lofexidine						
Methadone	Vehicle	0.144 (0.0429)	0.257 (0.0764)	0.457 (0.136)	0.813 (0.242)	1.45 (0.431)
Lofexidine	Vehicle	0.0196 (0.00433)	0.0348 (0.00771)	0.0620 (0.0137)	0.110 (0.0244)	0.196 (0.0435)
1 Methadone: 2 Lofexidine						
Methadone	Vehicle	0.0721 (0.0215)	0.128 (0.0382)	0.228 (0.0680)	0.407 (0.121)	0.724 (0.215)
Lofexidine	Vehicle	0.0293 (0.00650)	0.0522 (0.0166)	0.0930 (0.0206)	0.165 (0.0367)	0.295 (0.0652)
3 Methadone: 1 Lofexidine						
Methadone	Vehicle	0.216 (0.0644)	0.385 (0.115)	0.685 (0.204)	1.22 (0.363)	2.17 (0.646)
Lofexidine	Vehicle	0.00978 (0.00217)	0.0174 (0.00386)	0.0310 (0.00686)	0.0552 (0.0122)	0.0982 (0.0217)
2 Methadone: 1 Clonidine						
Methadone	Vehicle	0.144 (0.0429)	0.257 (0.0764)	0.457 (0.136)	0.813 (0.242)	1.45 (0.431)
Clonidine	Vehicle	0.00379 (0.000994)	0.00675 (0.00177)	0.0120 (0.00315)	0.0214 (0.00561)	0.0381 (0.00998)
1 Methadone: 1 Clonidine						
Methadone	Vehicle	0.0721 (0.0215)	0.128 (0.0382)	0.228 (0.0680)	0.406 (0.121)	0.724 (0.215)
Clonidine	Vehicle	0.00569 (0.00149)	0.0101 (0.00266)	0.0180 (0.00473)	0.0321 (0.00841)	0.0571 (0.0150)
4 Methadone: 1 Clonidine						
Methadone	Vehicle	0.216 (0.0644)	0.385 (0.115)	0.685 (0.204)	1.22 (0.363)	2.17 (0.646)
Clonidine	Vehicle	0.00190 (0.000467)	0.00338 (0.000885)	0.00601 (0.00158)	0.0107 (0.00280)	0.0190 (0.00499)
1 U69,593: 1 Lofexidine						
U69,593	Vehicle	0.346 (0.0471)	0.616 (0.0839)	1.10 (0.149)	1.95 (0.266)	3.47 (0.473)
Lofexidine	Vehicle	0.0177 (0.00346)	0.0316 (0.00616)	0.0562 (0.0110)	0.100 (0.0195)	0.178 (0.0348)
1 U69,593: 2 Lofexidine						
U69,593	Vehicle	0.173 (0.0236)	0.308 (0.0420)	0.548 (0.0747)	0.975 (0.133)	1.74 (0.237)
Lofexidine	Vehicle	0.0339 (0.00757)	0.0603 (0.135)	0.107 (0.0240)	0.191 (0.0427)	0.340 (0.760)
2 U69,593: 1 Lofexidine						
U69,593	Vehicle	0.519 (0.0707)	0.923 (0.126)	1.64 (0.224)	2.93 (0.399)	5.21 (0.710)
Lofexidine	Vehicle	0.0113 (0.00252)	0.0201 (0.00449)	0.0358 (0.00800)	0.0637 (0.0142)	0.113 (0.0253)
2 U69,593: 1 Clonidine						
U69,593	Vehicle	0.346 (0.0471)	0.616 (0.0839)	1.10 (0.149)	1.95 (0.266)	3.47 (0.473)
Clonidine	Vehicle	0.00382 (0.000956)	0.00680 (0.00170)	0.0121 (0.00303)	0.0215 (0.00539)	0.0384 (0.00960)
1 U69,593: 2 Clonidine						
U69,593	Vehicle	0.173 (0.0236)	0.308 (0.0420)	0.548 (0.0747)	0.975 (0.133)	1.74 (0.237)
Clonidine	Vehicle	0.00761 (0.00215)	0.0135 (0.00383)	0.0241 (0.00681)	0.0429 (0.0121)	0.0764 (0.0216)
3 U69,593: 1 Clonidine						
U69,593	Vehicle	0.519 (0.0707)	0.923 (0.126)	1.64 (0.224)	2.93 (0.399)	5.21 (0.710)
Clonidine	Vehicle	0.00254 (0.000717)	0.00451 (0.00128)	0.00803 (0.00227)	0.0143 (0.00404)	0.0255 (0.00720)

(Spaulding et al., 1979; Drasner and Fields, 1988; Tajerian et al., 2012; Stone et al., 2014). Additionally, our findings demonstrate that schedule-controlled responding supra-additive interactions at A_{2R} were not pharmacologically specific for MOR, as supra-additive interactions with A_{2R} agonists were observed with the KOR agonist U69,593. These results highlight the importance of the proportions of MOR agonists in complex drug mixtures on observed behavior. An additional consideration for these studies is that here we only examine schedule-controlled responding drug-drug interactions via isobolar analysis. Although we additionally studied hotplate antinociception and hypothermia in these animals, we are unable to determine whether these observed dose-response function shifts were subadditive, additive, or supra-additive. Additional experiments beyond the scope of

the current study would identify antinociceptive and hypothermic drug-drug additivity interactions.

Although not explicitly examined in the present study, supra-additive antinociception resulting from combinations of A_{2R} and KOR agonists has been reported (Ossipov, Harris et al., 1990; Roerig, 1995). Specifically, supra-additive antinociception was produced in rats using a tail withdrawal assay when three parts of clonidine and one part of U69,593 were administered intrathecally (Ossipov, Harris et al., 1990). Further, supra-additive antinociception was produced in mice using the tail withdrawal assay when one part of clonidine and one part of the KOR agonist U50-488H were administered intrathecally (Roerig, 1995). When compared with our additive KOR and A_{2R} schedule-controlled responding behavioral findings in rats, there




Fig. 7. Isobolographic analysis of reference A_{2R} agonists combined with MOR or KOR reference agonists. Ordinates, ED_{50} values of morphine (left panels), methadone (middle panels), and U69,593 (right panels) in mg/kg. Abscissae, ED_{50} values of lofexidine (upper panels) and clonidine (lower panels) in mg/kg. Each point represents the ED_{50} value and error bars represent 95% CIs. The points at which the line of additivity crosses the ordinates and abscissae represent the ED_{50} values of each compound alone. The line of additivity (dashed line) represents combinations of doses that would be predicted to produce a 50% effect if the compounds were strictly dose-additive. The vertical and horizontal lines around each data point represent the 95% CIs. *Indicates at least $P < 0.05$ difference between Z_{mix} and Z_{add} for a respective dose combination, denoting supra-additivity.

are a number of differences across the present and previous studies that may contribute to the observed differences in additive versus supra-additive drug effects (Ossipov, Harris et al., 1990; Roerig, 1995) including assays employed (i.e., antinociception versus schedule-controlled responding), the routes of administration of compounds (i.e., intraperitoneally vs. intrathecally), and drug history (i.e., a complex drug history vs. naive). These differences may individually and combined yield different receptor densities and receptor pools that mediate the underlying observed behavioral results.

The affinities of MG at both MOR and A_{2R} were approximately equal whereas the affinity of 7-OH-MG was high at the MOR (77.9 nM) and negligible at the A_{2R} . In our studies, MG failed to mimic the antinociceptive effects of MOR agonists or the hypothermic effects of A_{2R} agonists. These findings are in contrast to previously reported results that demonstrated that MG produced antinociceptive effects in C57BL/6J mice (Chakraborty et al., 2021). Additionally, neither naltrexone nor yohimbine antagonized MG-induced

decreases in food-maintained behavior. Under the same experimental conditions, naltrexone antagonized the effects of MOR agonists, and yohimbine antagonized the effects of A_{2R} agonists. In contrast to MG, 7-OH-MG mimicked the effects of morphine and methadone. Superficially, these MG results suggest no contribution of the MOR or A_{2R} to the pharmacological effects of MG in rats. However, as the discriminative-stimulus effects of MG in rats were antagonized by naltrexone, our current results do not broadly apply to all in vivo pharmacological assessments (Obeng, Wilkerson et al., 2021). Additionally, in a neuropathic pain model, the antiallodynic effects of MG in rats were antagonized by yohimbine (Foss et al., 2020). The inability of naltrexone to antagonize the rate-decreasing effects of MG has previously been reported (Hiranita et al., 2019; Obeng, Wilkerson et al., 2021). Naltrexone was 3.2-fold less potent in antagonizing the rate-decreasing effects of morphine than in antagonizing the discriminative-stimulus effects of morphine in rats (Obeng, Wilkerson et al., 2021). Thus, the

TABLE 4

Theoretical Zadd (mg/kg), experimental Zmix (mg/kg), with CIs, and observed interactive effects of studied compound mixtures

Combination	Zadd	Zmix	Interactive Effect
1 Morphine: 1 Lofexidine	9.13 (6.55–11.71)	2.88 (1.94–3.81)	Supra-additive
1 Morphine: 2 Lofexidine	9.00 (6.45–11.54)	1.42 (0.932–1.91)	Supra-additive
3 Morphine: 1 Lofexidine	9.22 (3.14–15.31)	4.00 (2.23–6.23)	Additive
2 Morphine: 1 Clonidine	9.26 (6.64–11.84)	2.90 (1.15–4.66)	Supra-additive
1 Morphine: 2 Clonidine	9.24 (6.63–11.86)	1.57 (1.06–2.08)	Supra-additive
3 Morphine: 1 Clonidine	9.26 (6.65–11.88)	5.73 (3.50–7.95)	Additive
1 Methadone: 1 Lofexidine	0.604 (0.541–0.668)	0.514 (0.084–0.944)	Additive
1 Methadone: 2 Lofexidine	0.540 (0.159–0.922)	0.237 (0.170–0.304)	Additive
3 Methadone: 1 Lofexidine	0.660 (0.279–1.04)	0.767 (0.488–1.05)	Additive
2 Methadone: 1 Clonidine	0.683 (0.608–0.757)	0.280 (0.137–0.424)	Supra-additive
1 Methadone: 1 Clonidine	0.672 (0.415–0.930)	0.183 (0.0261–0.340)	Supra-additive
4 Methadone: 1 Clonidine	0.688 (0.590–0.786)	0.680 (0.224–1.14)	Additive
1 U69,593: 1 Lofexidine	2.033 (1.71–2.35)	1.01 (0.907–1.108)	Supra-additive
1 U69,593: 2 Lofexidine	1.91 (1.25–2.57)	0.484 (0.395–0.573)	Supra-additive
2 U69,593: 1 Lofexidine	2.102 (1.73–2.47)	1.23 (0.903–1.56)	Supra-additive
2 U69,593: 1 Clonidine	2.16 (1.82–2.50)	0.735 (0.189–1.28)	Supra-additive
1 U69,593: 2 Clonidine	2.12 (1.73–2.51)	0.567 (0.462–0.672)	Supra-additive
3 U69,593: 1 Clonidine	2.17 (1.82–2.51)	1.63 (1.38–1.87)	Additive

sensitivity to the pharmacological activity of interest differs across experimental assays employed.

Both MG and 7-OH-MG potentiated the rate-decreasing effects of lofexidine and clonidine, but not those of morphine and methadone, and increased the maximum antinociceptive effects of the A_{2R} agonists. However, MG, but not 7-OH-MG, potentiated the hypothermic effects of the reference A_{2R} agonists. The MG-induced potentiation of the hypothermic and antinociceptive effects of the reference A_{2R} agonists might suggest positive allosteric effects of MG at the A_{2R} ; however, there is currently no such published report or supportive evidence. Nonetheless, there are clinical implications in that MG can be used to enhance the clinical effects of A_{2R} agonists such as pain relief as well as the ability to block the acute withdrawal symptoms in chronic opioid users. Additionally, the in vivo “apparent” positive allosteric effects of MG at the A_{2R} might indicate a challenging hypothesis that MG could mitigate opioid withdrawal (Wilson et al., 2020; Wilson et al., 2021) primarily due to allosteric agonism at the A_{2R} rather than dual agonism at the MOR and A_{2R} (Chakraborty et al., 2021). It is worth noting that MG is metabolized by CYP3A4 to 7-OH-MG (Kamble et al., 2020; Basiliere and Kerrigan, 2020; Chakraborty et al., 2021). It was recently reported that metabolic conversion of 7-OH-MG does not contribute to MG pharmacological activity (Berthold et al., 2022). However, other studies showed that 7-OH MG does contribute to the analgesic and respiratory depressive effects of MG, albeit its contribution was found to be limited by metabolic saturation (Kruegel et al., 2019; Chakraborty et al., 2021; Hill et al., 2022). Berthold et al. (2022) demonstrated that in mice treated with MG doses, which produced significant hotplate antinociception, 7-OH-MG brain levels remained significantly below the observed 7-OH-MG brain levels found in 7-OH-MG treated mice that were dosed sufficiently to produce acute antinociception. In this study, the pharmacological activity of 7-OH-MG was quite different from that of MG, which contradicts the hypothesis that 7-OH-MG is responsible for the “apparent” antinociceptive effects of MG in mice (Kruegel et al., 2019). The inconsistency between the present and previous (Kruegel et al., 2019) studies might simply be due to a difference in species (i.e., rat vs. mouse, respectively).

To assess the therapeutic utility of these kratom alkaloids, future studies should examine the subadditive and additive versus supra-additive effects of MG, 7-OH-MG, and MOR as well as A_{2R} agonists in relevant pathologic pain and drug dependence models. In conclusion, supra-additive interaction between agonism at the MOR and A_{2R} depend on the dose combination ratio and MOR agonist used. Affinity of MG at these receptors was approximately equal whereas no considerable affinity of 7-OH-MG was found at the A_{2R} .

Acknowledgments

The authors would like to thank Ms. Danielle M. Sevier and Samantha N. Hart at the College of Pharmacy, University of Florida, for administrative assistance.

Authorship Contributions

Participated in research design: Obeng, Hampson, McMahon, Hiranita.
Conducted experiments: Obeng, Patel, Restrepo, Gamez-Jimenez, Ho, Guerrero Calvache, Pallares, Helmes.
Contributed new reagents or analytic tools: Leon, McCurdy.
Performed data analysis: Obeng, Zuarth Gonzalez, Chaves Da Silva, Restrepo, Guerrero Calvache, Shiomitsu, Soto, Wilkerson, Hiranita.
Wrote or contributed to the writing of the manuscript: Obeng, Leon, Zuarth Gonzalez, Chaves Da Silva, Shiomitsu, Soto, McCurdy, McMahon, Wilkerson, Hiranita.

References

- Arnsten AF and Li B-M (2005) Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. *Biol Psychiatry* **57**:1377–1384.
- Basiliere S and Kerrigan S (2020) CYP450-mediated metabolism of mitragynine and investigation of metabolites in human urine. *J Anal Toxicol* **44**:301–313.
- Berthold EC, Kamble SH, Raju KS, Kuntz MA, Senetra AS, Mottinelli M, León F, Restrepo LF, Patel A, Ho NP, et al. (2022) The lack of contribution of 7-hydroxymitragynine to the antinociceptive effects of mitragynine in mice: a pharmacokinetic and pharmacodynamic study. *Drug Metab Dispos* **50**:158–167.
- Boxwalla M, Matwyshyn G, Puppala BL, Andurkar SV, and Gulati A (2010) Involvement of imidazoline and opioid receptors in the enhancement of clonidine-induced analgesia by sulfisoxazole. *Can J Physiol Pharmacol* **88**:541–552.
- Brede M, Philipp M, Knaus A, Muthig V, and Hein L (2004) α 2-adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models. *Biol Cell* **96**:343–348.
- Chakraborty S, Uprety R, Slocum ST, Irie T, Le Rouzic V, Li X, Wilson LL, Scouller B, Alder AF, Kruegel AC, et al. (2021) Oxidative metabolism as a modulator of kratom's biological actions. *J Med Chem* **64**:16553–16572.
- Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction. *Biochem Pharmacol* **22**:3099–3108.
- Clemow DB and Walker DJ (2014) The potential for misuse and abuse of medications in ADHD: a review. *Postgrad Med* **126**:64–81.

- Crassous P-A, Denis C, Paris H, and Sénard JM (2007) Interest of α 2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives. *Curr Top Med Chem* **7**:187–194.
- Drasner K and Fields HL (1988) Synergy between the antinociceptive effects of intrathecal clonidine and systemic morphine in the rat. *Pain* **32**:309–312.
- Ellis CR, Racz R, Kruhlak NL, Kim MT, Zakharov AV, Southall N, Hawkins EG, Burkhart K, Strauss DG, and Stavitskaya L (2020) Evaluating kratom alkaloids using PHASE. *PLoS One* **15**:e0229646.
- Foss JD, Nayak SU, Tallarida CS, Farkas DJ, Ward SJ, and Rawls SM (2020) Mitragynine, bioactive alkaloid of kratom, reduces chemotherapy-induced neuropathic pain in rats through α -adrenoceptor mechanism. *Drug Alcohol Depend* **209**:107946.
- Giovannoni MP, Ghelardini C, Vergelli C, and Dal Piaz V (2009) α 2-agonists as analgesic agents. *Med Res Rev* **29**:339–368.
- Gowing L, Farrell M, Ali R, and White JM (2016). Alpha2-adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev* **5**:CD002024.
- Hao S, Takahata O, and Iwasaki H (2000) Intrathecal endomorphin-1 produces antinociceptive activities modulated by alpha 2-adrenoceptors in the rat tail flick, tail pressure and formalin tests. *Life Sci* **66**:PL195–PL204.
- Haq N, McMahan VM, Torres A, Santos G-M, Knight K, Kushel M, and Coffin PO (2021) Race, pain, and opioids among patients with chronic pain in a safety-net health system. *Drug Alcohol Depend* **222**:108671.
- Harun N, Hassan Z, Navaratnam V, Mansor SM, and Shoaib M (2015) Discriminative stimulus properties of mitragynine (kratom) in rats. *Psychopharmacology (Berl)* **232**:2227–2238.
- Hill R, Kruegel AC, Javitch JA, Lane JR and Canals M (2022) The respiratory depressant effects of mitragynine are limited by its conversion to 7-OH mitragynine. *Br J Pharmacol* **179**:3875–3885.
- Hiranita T, Leon F, Felix JS, Restrepo LF, Reeves ME, Pennington AE, Obeng S, Avery BA, McCurdy CR, McMahon LR, et al. (2019) The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats. *Psychopharmacology (Berl)* **236**:2725–2734.
- Kamble SH, León F, King TI, Berthold EC, Lopera-Londoño C, Siva Rama Raju K, Hampson AJ, Sharma A, Avery BA, McMahon LR, et al. (2020) Metabolism of a kratom alkaloid metabolite in human plasma increases its opioid potency and efficacy. *ACS Pharmacol Transl Sci* **3**:1063–1068.
- Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, Ansonoff M, Gassaway MM, Pintar JE, Pasternak GW, et al. (2019) 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. *ACS Cent Sci* **5**:992–1001.
- Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, and Boyer EW (2016) Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. *J Med Toxicol* **12**:341–349.
- Matsumoto K, Mizowaki M, Suchitra T, Murakami Y, Takayama H, Sakai S, Aimi N, and Watanabe H (1996) Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. *Eur J Pharmacol* **317**:75–81.
- Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, and Davis NL (2021) Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. *MMWR Morb Mortal Wkly Rep* **70**:202–207.
- Meert TF and De Kock M (1994) Potentiation of the analgesic properties of fentanyl-like opioids with alpha 2-adrenoceptor agonists in rats. *Anesthesiology* **81**:677–688.
- Montgomery LS (2022) Pain management with opioids in adults. *J Neurosci Res* **100**:10–18.
- O'Rourke MF, Blaxall HS, Iversen LJ, and Bylund DB (1994) Characterization of [3H]RX821002 binding to alpha-2 adrenergic receptor subtypes. *J Pharmacol Exp Ther* **268**:1362–1367.
- Obeng S, Hiranita T, León F, McMahon LR, and McCurdy CR (2021) Novel approaches, drug candidates, and targets in pain drug discovery. *J Med Chem* **64**:6523–6548.
- Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJY, Ramanathan S, Sharma A, León F, et al. (2020) Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids. *J Med Chem* **63**:433–439.
- Obeng S, Wilkerson JL, León F, Reeves ME, Restrepo LF, Gamez-Jimenez LR, Patel A, Pennington AE, Taylor VA, Ho NP, et al. (2021) Pharmacological comparison of mitragynine and 7-hydroxymitragynine: in vitro affinity and efficacy for mu-opioid receptor and opioid-like behavioral effects in rats. *J Pharmacol Exp Ther* **376**:410–427.
- Ossipov MH, Harris S, Lloyd P, and Messineo E (1990) An isobolographic analysis of the antinociceptive effect of systemically and intrathecally administered combinations of clonidine and opiates. *J Pharmacol Exp Ther* **255**:1107–1116.
- Ossipov MH, Lozito R, Messineo E, Green J, Harris S, and Lloyd P (1990) Spinal antinociceptive synergy between clonidine and morphine, U69593, and DPDPE: isobolographic analysis. *Life Sci* **47**:PL71–PL76.
- Plummer JL, Cmielewski PL, Gourlay GK, Owen H, and Cousins MJ (1992) Antinociceptive and motor effects of intrathecal morphine combined with intrathecal clonidine, noradrenaline, carbachol or midazolam in rats. *Pain* **49**:145–152.
- R Core Team (2017) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>.
- Roerig SC (1995) Decreased spinal morphine/clonidine antinociceptive synergism in morphine-tolerant mice. *Life Sci* **56**:PL115–PL122.
- Shamima AR, Fakurazi S, Hidayat MT, Hairuszah I, Moklas MAM, and Arulsevan P (2012) Antinociceptive action of isolated mitragynine from *Mitragyna Speciosa* through activation of opioid receptor system. *Int J Mol Sci* **13**:11427–11442.
- Sharma A, Kamble SH, León F, Chear NJ, King TI, Berthold EC, Ramanathan S, McCurdy CR, and Avery BA (2019) Simultaneous quantification of ten key Kratom alkaloids in *Mitragyna speciosa* leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry. *Drug Test Anal* **11**:1162–1171.
- Singh D, Müller CP, and Vicknasingam BK (2014) Kratom (*Mitragyna speciosa*) dependence, withdrawal symptoms and craving in regular users. *Drug Alcohol Depend* **139**:132–137.
- Snedecor GW and Cochran WG (1967) *Statistical Methods*, Iowa State University Press, Ames, IA.
- Spaulding TC, Fielding S, Venafro JJ, and Lal H (1979) Antinociceptive activity of clonidine and its potentiation of morphine analgesia. *Eur J Pharmacol* **58**:19–25.
- Stone LS, German JP, Kitto KF, Fairbanks CA, and Wilcox GL (2014) Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects. *PLoS One* **9**:e109903.
- Stone LS, MacMillan LB, Kitto KF, Limbird LE, and Wilcox GL (1997) The α 2a adrenergic receptor subtype mediates spinal analgesia evoked by α 2 agonists and is necessary for spinal adrenergic-opioid synergy. *J Neurosci* **17**:7157–7165.
- Tajerian M, Millicamps M, and Stone LS (2012) Morphine and clonidine synergize to ameliorate low back pain in mice. *Pain Res Treat* **2012**:150842.
- Tal M, Silberstein A, and Nusser E (1985) Why does Coomassie Brilliant Blue R interact differently with different proteins? A partial answer. *J Biol Chem* **260**:9976–9980.
- Tallarida RJ (2000) *Drug Synergism and Dose-Effect Data Analysis*, CRC Press, Boca Raton, FL.
- Tallarida RJ (2001) Drug synergism: its detection and applications. *J Pharmacol Exp Ther* **298**:865–872.
- Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. *J Pharmacol Exp Ther* **319**:1–7.
- Tonner PH (2017) Additives used to reduce perioperative opioid consumption 1: Alpha2-agonists. *Best Pract Res Clin Anaesthesiol* **31**:505–512.
- Ullman-Culleré MH and Foltz CJ (1999) Body condition scoring: a rapid and accurate method for assessing health status in mice. *Lab Anim Sci* **49**:319–323.
- Valverde A and Skelding AM (2019) Alternatives to opioid analgesia in small animal anesthesia: alpha-2 agonists. *Vet Clin North Am Small Anim Pract* **49**:1013–1027.
- Váradi A, Marrone GF, Palmer TC, Narayan A, Szabó MR, Le Rouzic V, Grinnell SG, Subrath JJ, Warner E, Kalra S et al. (2016) Mitragynine/corynantheidine pseudoin-doxyls as opioid analgesics with Mu agonism and delta antagonism, which do not recruit β -arrestin-2. *J Med Chem* **59**:8381–8397.
- Walker SM, Goudas LC, Cousins MJ, and Carr DB (2002) Combination spinal analgesic chemotherapy: a systematic review. *Anesth Analg* **95**:674–715.
- Wilkerson JL, Felix JS, Restrepo LF, Ansari MI, Coop A, and McMahon LR (2019) The effects of morphine, buprenorphine, and buprenorphine alone and in combination on schedule-controlled responding and hot plate antinociception in rats. *J Pharmacol Exp Ther* **370**:380–389.
- Wilkerson JL, Ghosh S, Mustafa M, Abdullah RA, Niphakis MJ, Cabrera R, Maldonado RL, Cravatt BF, and Lichtman AH (2017) The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. *Neuropharmacology* **114**:156–167.
- Wilkerson JL, Niphakis MJ, Grim TW, Mustafa MA, Abdullah RA, Poklis JL, Dewey WL, Akbarali H, Banks ML, Wise LE, et al. (2016) The selective monoacylglycerol lipase inhibitor MJN110 produces opioid-sparing effects in a mouse neuropathic pain model. *J Pharmacol Exp Ther* **357**:145–156.
- Wilson LL, Chakraborty S, Eans SO, Cirino TJ, Stacy HM, Simons CA, Uprety R, Majumdar S, and McLaughlin JP (2021) Kratom alkaloids, natural and semi-synthetic, show less physical dependence and ameliorate opioid withdrawal. *Cell Mol Neurobiol* **41**:1131–1143.
- Wilson LL, Harris HM, Eans SO, Brice-Tutt AC, Cirino TJ, Stacy HM, Simons CA, León F, Sharma A, Boyer EW, et al. (2020) Lyophilized kratom tea as a therapeutic option for opioid dependence. *Drug Alcohol Depend* **216**:108310.

Address correspondence to: Jenny L. Wilkerson, Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, Amarillo Research Building, Rm 1107, 1406 S. Coulter, Amarillo, TX 79106. E-mail: Jenny.Wilkerson@ttuhsc.edu; or Takato Hiranita, Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, Amarillo Research Building, Rm 1109, 1406 S. Coulter, Amarillo, TX 79106. E-mail: takatohiranita@cop.ufl.edu